Absorption-enhanced resveratrol (micronized, micellar, liposomal or other solubilized forms, or resveratrol taken with piperine) raises blood resveratrol more than the same dose of standard trans-resveratrol.
7 sources: 6 positive, 1 negative.
Researchers say
No researcher counted yet.
Studies show
6 positive, 1 negative
7 papers we read
-
Controlled trial, Cancer Prev Res (Phila), 2011, PMID 21680702
Positive Study
Read the paper on PubMed →The pharmacokinetic analysis revealed that the mean plasma Cmax for resveratrol measured after ingestion of SRT501 (mean 1942 ng/mL , CV:73.3%) was 3.6-fold higher than that achieved following a single dose of non-micronized resveratrol in healthy volunteers (mean 538.8 ng/mL (CV:72.5%), consistent with the superior bioavailability of resveratrol when administered as SRT501 compared to non-micronized agent.
-
Other primary study, Pharmaceutics, 2020, PMID 33302446
Positive Study
Read the paper on PubMed →The 150 mg dose of Veri-Sperse® had a 2-fold increase in absorption (AUC) and a 3-fold increase in Cmax of trans-resveratrol conjugates compared to 150 mg Veri-te.
-
Other primary study, Front Nutr, 2020, PMID 34422874
Positive Study
Read the paper on PubMed →In all subjects, the blood concentration of resveratrol following Resv@MDH administration was higher than that with pure resveratrol.
-
Other primary study, ACS Omega, 2022, PMID 35474815
Positive Study
Read the paper on PubMed →Upon pharmacokinetic studies on healthy human subjects (n = 16) following a randomized, double-blinded, placebo-controlled, 2-arm, 4-sequence crossover design and tandem mass spectrometry (UPLC-ESI-MS/MS), 80 mg of trans-resveratrol from RF-20 provided enhanced free resveratrol bioavailability and pharmacokinetic properties compared to the unformulated resveratrol with 98% purity.
-
Other primary study, AAPS Open, 2022, PMID 35789594
Positive Study
Read the paper on PubMed →At 50 mg/kg resveratrol delivered as the 5% dose loaded solubilization product, the Cmax (average highest maximum concentration in blood plasma) was 17 fold higher than with unformulated API and more than 10 fold higher than micronized Mega Resveratrol.
-
Controlled trial, Sci Rep, 2025, PMID 40628835
Positive Study
Read the paper on PubMed →Compared to T2, the modified formulation of T1 significantly enhanced the absorption rate, extent, and relative bioavailability of resveratrol.
-
Controlled trial, Eur J Cancer Prev, 2021, PMID 32868637
Negative Study
Read the paper on PubMed →The coadministration of resveratrol with piperine at 5 and 25 mg doses did not sufficiently alter the pharmacokinetics of resveratrol or resveratrol glucuronide to demonstrate the significant enhancement observed in murine modeling.
3 more not counted · see why
Show the receipts from 7 sources
-
Controlled trial, Cancer Prev Res (Phila), 2011, PMID 21680702 Study · positive
The pharmacokinetic analysis revealed that the mean plasma Cmax for resveratrol measured after ingestion of SRT501 (mean 1942 ng/mL , CV:73.3%) was 3.6-fold higher than that achieved following a single dose of non-micronized resveratrol in healthy volunteers (mean 538.8 ng/mL (CV:72.5%), consistent with the superior bioavailability of resveratrol when administered as SRT501 compared to non-micronized agent.
-
Other primary study, Pharmaceutics, 2020, PMID 33302446 Study · positive
The 150 mg dose of Veri-Sperse® had a 2-fold increase in absorption (AUC) and a 3-fold increase in Cmax of trans-resveratrol conjugates compared to 150 mg Veri-te.
-
Other primary study, Front Nutr, 2020, PMID 34422874 Study · positive
In all subjects, the blood concentration of resveratrol following Resv@MDH administration was higher than that with pure resveratrol.
-
Other primary study, ACS Omega, 2022, PMID 35474815 Study · positive
Upon pharmacokinetic studies on healthy human subjects (n = 16) following a randomized, double-blinded, placebo-controlled, 2-arm, 4-sequence crossover design and tandem mass spectrometry (UPLC-ESI-MS/MS), 80 mg of trans-resveratrol from RF-20 provided enhanced free resveratrol bioavailability and pharmacokinetic properties compared to the unformulated resveratrol with 98% purity.
-
Other primary study, AAPS Open, 2022, PMID 35789594 Study · positive
At 50 mg/kg resveratrol delivered as the 5% dose loaded solubilization product, the Cmax (average highest maximum concentration in blood plasma) was 17 fold higher than with unformulated API and more than 10 fold higher than micronized Mega Resveratrol.
-
Controlled trial, Sci Rep, 2025, PMID 40628835 Study · positive
Compared to T2, the modified formulation of T1 significantly enhanced the absorption rate, extent, and relative bioavailability of resveratrol.
-
Controlled trial, Eur J Cancer Prev, 2021, PMID 32868637 Study · negative
The coadministration of resveratrol with piperine at 5 and 25 mg doses did not sufficiently alter the pharmacokinetics of resveratrol or resveratrol glucuronide to demonstrate the significant enhancement observed in murine modeling.